Researcher Gary Gibson talks at Burke in White Plains about a trial on a new treatment for Alzheimer’s that uses Benfotiamine ...
MyChesCo on MSN8h
YPrime Releases Report on Enhancing Clinical Trial TechnologyYPrime has unveiled a pivotal research report titled “A Sponsor’s Guide to Leveraging Site Insights for Smarter Technology ...
Prostate cancer disproportionately affects Black men, leading to higher mortality rates and worse health outcomes compared to ...
Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial ...
Medical Xpress on MSN3d
Clinical trial supports adding ruxolitinib to tyrosine kinase inhibitors for chronic myeloid leukemiaResearchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase ...
12h
Pasithea Therapeutics Corp. (KTTA) reported positive initial results from its Phase 1 clinical trial of PAS-004, a new ...
The findings highlight the potential harms associated with receiving placebo in placebo-controlled IBD trials, "which might ...
Headlands Research, a clinical trial site network with locations across the United States and Canada, is launching its newest ...
Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN).
The average readability of informed consent forms of federally funded clinical trials exceeds the reading comprehension ...
Wells Fargo analyst Mohit Bansal maintained a Hold rating on Amgen (AMGN – Research Report) yesterday and set a price target of $335.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback